Lion's Mane And Nerve Growth Factor: Reading The Studies

The Lion's Mane nerve growth factor research is, with one category of exception, laboratory work: compounds added to cultured cells, and extracts fed to rodents. No published human trial of Hericium erinaceus has measured nerve growth factor in a participant. The two trials usually cited as proof of the mechanism measured test scores and mood scales instead, and both say so in their own discussion sections.

That gap is where the category does its selling. "Nerve growth factor" sounds like a measured outcome, so a sentence pairing the mushroom with the protein reads as though someone took a blood sample. Read the papers and the chain is longer and more conditional than the marketing version.

What nerve growth factor is, and what the cell experiments did

Nerve growth factor is a protein, one of the neurotrophins. In the Hericium literature it appears as an outcome in cell culture: researchers expose a cell line to a compound and measure how much nerve growth factor the cells make or release.

The important detail is which cells. A 2025 systematic review of preclinical models in Frontiers in Pharmacology reports that erinacines stimulated nerve growth factor synthesis in vitro only when applied to glial cells — the non-neuronal support cells of nervous tissue. Erinacines A, C and S induced release from astrocytic 1321N1 cells. Erinacine A potentiated neurite outgrowth in primary cortical neurons, but only in the presence of added nerve growth factor. In PC12 cells without added nerve growth factor, erinacines stimulated neither synthesis nor outgrowth.

Concentration matters as much as cell type. A 2018 review in Behavioural Neurology tabulates these cell studies mostly between 1 mM and 70.8 mM, with erinacine A inducing around 250 pg/ml at 1 mM. Those are millimolar exposures in a dish, and the 2025 review states outright that it provides no translation of animal doses to human ones.

The blood–brain barrier question, where the reviews contradict each other

For a compound eaten by mouth to act inside the brain, it has to get there. The two reviews read that evidence differently.

The 2025 Frontiers in Pharmacology review states in its introduction that some erinacines and hericenones easily cross the blood–brain barrier by passive diffusion, citing two earlier papers, and does not test this itself. The 2018 Behavioural Neurology review states that no direct evidence shows erinacines cross the blood–brain barrier, and lists erinacine A's unproven brain penetration among its own limitations.

Both are peer-reviewed, seven years apart, and they disagree on a load-bearing step. That is worth knowing before you read a confident sentence about this mushroom and the brain.

Where nerve growth factor itself was measured: rodent tissue

The 2025 review reports that mycelial preparations with high erinacine A content raised hippocampal nerve growth factor in APP/PS1 mice, and that this occurred selectively in astrocytes rather than throughout the tissue. That is the clearest nerve growth factor measurement in the body of work, and it is mouse brain tissue, transgenic model, mycelial material.

The 2018 review sets out the dosing behind this family of rodent studies. In APPswe/PS1dE9 transgenic mice, enriched mycelia were given orally for 30 days from five months of age at 300 mg/kg, with erinacine A or S at 30 mg/kg. In rats, erinacine A-enriched mycelia at 50 and 300 mg/kg over five days were reported to reduce infarct volume after induced ischaemia by 22% and 44%.

Animal and in-vitro findings describe animals and cells. The 2025 review names the reasons not to extend them: strains, growth conditions and extraction methods frequently unreported, erinacines often unquantified, binding targets unknown, most in vivo work in male animals only, and no pharmacokinetic data.

What the two human trials measured instead

Mori and colleagues, 2009 Docherty and colleagues, 2023
Design Double-blind, placebo-controlled Double-blind, placebo-controlled pilot
Population 30 Japanese adults, 50–80, mild cognitive impairment; 29 analysed 43 healthy adults, 18–45; 41 analysed at day 29
Dose and form Twelve 250 mg tablets daily, each 96% dried fruiting-body powder Three 600 mg capsules each morning
Duration 16 weeks, plus four weeks off Mean 28.5 days
Measured A 30-point scale adapted from the Revised Hasegawa Dementia Scale Cognitive task battery, mood and stress scales
Nerve growth factor measured? No No

Mori and colleagues, in Phytotherapy Research in 2009, state that the active ingredients and mechanism were not determined, that their hericenone explanation was speculative, and that it is unknown whether these compounds act the same way in human cells or cross the blood–brain barrier. Docherty and colleagues, in Nutrients in 2023, describe a small pilot, likely underpowered, needing replication, with no human bioavailability data to guide sampling time — and their paper does not state whether the material used was fruiting body or mycelium.

For the species groundwork, read what Lion's Mane actually is; and what Cordyceps is for the other mushroom in the tube. The rest is in our guides index.

What is in a Chaski tube

A tube holds 600 g of 77% dark chocolate buttons, 77% meaning the share by weight from the cacao bean. The listed components are single-origin Peruvian and Ecuadorian cacao, coconut sugar, Lion's Mane as a fruiting body extract, Cordyceps sinensis as mycelium, and Ginkgo Biloba, which is in the process of being replaced by 200 mg of Tremella fuciformis (10:1 fruiting body extract) per daily dose. No emulsifiers, no seed oils, no palm oil, no added cane sugar. The cacao is low-temperature ground, and every batch is tested for lead, cadmium and pesticides. Daily dose on the pack is four buttons. One tube is £44.99; three are £98.97, or £32.99 each.

Our Lion's Mane is a fruiting body extract. Most of the nerve growth factor work above used mycelial material, a different starting substance, and we hold no assay for any compound named on this page. The component list and pack detail are on the Chaski Cacao page.

Frequently Asked Questions

Has any human study measured nerve growth factor after taking Lion's Mane?

Not in the two trials most often cited. Mori and colleagues, in Phytotherapy Research in 2009, measured a 30-point cognitive scale in 30 adults aged 50 to 80 with mild cognitive impairment over 16 weeks, and took no nerve growth factor measurement. Docherty and colleagues, in Nutrients in 2023, measured a cognitive task battery plus mood and stress scales in 43 healthy adults aged 18 to 45 over roughly 28 days, and measured neither nerve growth factor nor brain-derived neurotrophic factor. In both papers the protein appears only in the discussion, as a proposed mechanism from cell and rodent work.

Which cells produced nerve growth factor in the laboratory studies?

Glial cells, not neurons. The 2025 systematic review in Frontiers in Pharmacology reports that erinacines stimulated nerve growth factor synthesis in vitro only when applied to glial cells, the support cells of nervous tissue. Erinacines A, C and S induced release from astrocytic 1321N1 cells. Erinacine A increased neurite outgrowth in primary cortical neurons only when nerve growth factor had already been added. In PC12 cells with no added nerve growth factor, erinacines produced neither synthesis nor outgrowth. The cell type and the pre-existing conditions both shaped the result.

Do erinacines reach the brain?

The two reviews disagree, which is worth knowing. The 2025 Frontiers in Pharmacology review says in its introduction that some erinacines and hericenones easily cross the blood-brain barrier by passive diffusion, citing two earlier papers, and does not test this itself. The 2018 Behavioural Neurology review states that no direct evidence shows erinacines cross the blood-brain barrier, and lists erinacine A's unproven brain penetration as one of its own limitations. Mori and colleagues in 2009 also described blood-brain barrier passage for these compounds as unknown.

Why does fruiting body versus mycelium keep coming up?

Because the compound families differ by part. The 2025 review describes hericenones as occurring exclusively in the fruiting body and erinacines as mainly mycelial, while the 2018 review reports that the fruiting body was found to contain no erinacines, and proposes submerged fermentation to grow mycelium enriched to at least 3 mg per gram. Most of the rodent nerve growth factor work used enriched mycelial preparations. A fruiting body extract and a mycelial one are therefore not substitutes when reading this particular literature, whatever the pack says.

Sources

  1. Spangenberg ET et al., Frontiers in Pharmacology, 2025 — systematic review of preclinical models.
  2. Li IC et al., Behavioural Neurology, 2018 — narrative review of cell and rodent studies.
  3. Mori K et al., Phytotherapy Research, 2009 — randomised, double-blind, placebo-controlled trial.
  4. Docherty S et al., Nutrients, 2023 — randomised, double-blind, placebo-controlled pilot trial.
Liquid error (sections/pagefly-section line 6): Could not find asset snippets/pf-6bdf23d6.liquid